Payment overview · 2025
General Payments
$437.73
16 reported records · 8 companies
Healthcare provider profile · identity verified
Robert Ferguson, MD
Allopathic & Osteopathic Physicians|Family Medicine · PINE BLUFF, AR · NPI 1336646496
Verified facts
What the public records show
CMS Open Payments records show Robert Ferguson, MD received $437.73 in general payments during 2025 across 16 reported records.
INTUITIVE SURGICAL, INC. accounted for 43.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $189.31 | 43.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.41 | 19.5% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.80 | 11.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.66 | 8.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.36 | 7.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.66 | 3.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.36 | 3.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.17 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $248.42 | 14 |
| Travel and Lodging | $189.31 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $189.31 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $85.41 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.80 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.36 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.36 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 384 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 355 | 100 |
| Lisinopril | Lisinopril | 304 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 293 | 59 |
| Omeprazole | Omeprazole | 276 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 273 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 243 | 62 |
| Gabapentin | Gabapentin | 226 | 56 |
| Losartan Potassium | Losartan Potassium | 224 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 52 |
| Eliquis | Apixaban | 163 | 30 |
| Metformin Hcl | Metformin Hcl | 143 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 53 |
| Sertraline Hcl | Sertraline Hcl | 137 | 45 |
| Tramadol Hcl | Tramadol Hcl | 127 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 125 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 28 |
| Simvastatin | Simvastatin | 121 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 30 |
| Carvedilol | Carvedilol | 106 | 26 |
| Meloxicam | Meloxicam | 99 | 28 |
| Allopurinol | Allopurinol | 98 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 28 |
| Furosemide | Furosemide | 90 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 26 |
| Potassium Chloride | Potassium Chloride | 82 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 16 |
| Lorazepam | Lorazepam | 78 | 15 |
| Trazodone Hcl | Trazodone Hcl | 78 | 26 |
| Bupropion Xl | Bupropion Hcl | 77 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 14 |
| Jardiance | Empagliflozin | 70 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 21 |
| Metformin Hcl Er | Metformin Hcl | 65 | 18 |
| Pregabalin | Pregabalin | 64 | 12 |
| Spironolactone | Spironolactone | 63 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 14 |
| Famotidine | Famotidine | 57 | 18 |
| Ozempic | Semaglutide | 56 | 11 |
| Methylprednisolone | Methylprednisolone | 54 | 44 |
| Buspirone Hcl | Buspirone Hcl | 51 | 18 |
| Glipizide | Glipizide | 51 | 15 |
| Donepezil Hcl | Donepezil Hcl | 50 | 13 |
| Atenolol | Atenolol | 49 | suppressed |
| Temazepam | Temazepam | 49 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | suppressed |
| Prednisone | Prednisone | 48 | 24 |
| Irbesartan | Irbesartan | 47 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | 11 |
| Montelukast Sodium | Montelukast Sodium | 45 | 12 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Alprazolam | Alprazolam | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 11 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Finasteride | Finasteride | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Sucralfate | Sucralfate | 39 | 12 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Estradiol | Estradiol | 37 | 15 |
| Glipizide Er | Glipizide | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 34 |
| Baclofen | Baclofen | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 14 |
| Azelastine Hcl | Azelastine Hcl | 30 | 15 |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 23 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Sulindac | Sulindac | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 17 |
| Olanzapine | Olanzapine | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 12 |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Flovent Hfa | Fluticasone Propionate | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $437.73 · 16 records | INTUITIVE SURGICAL, INC. | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, Da Vinci Surgical System, EVENITY, MOUNJARO, The Cologuard Plus Collection Kit, VRAYLAR, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error